COMPANY

Phanes Therapeutics

HQ: San Diego, CA source · phanesthera.com ↗ · West Coast

Keywords: oncology immuno-oncology Pancreatic Ductal Adenocarcinoma Gastric or Gastroesophageal Junction Adenocarcinoma Biliary Tract Cancer Colorectal Cancer Small Cell Lung Cancer Large Cell Neuroendocrine Cancer Neuroendocrine Prostate Cancer Gastroenteropancreatic Neuroendocrine Carcinoma Neuroendocrine Carcinomas Extrapulmonary Neuroendocrine Carcinoma Non Small Cell Lung Cancer Spevatamig (PT886) TAS 102 Mavrostobart (PT199)

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Raises and deals from press releases

Deal Deal · amount not disclosed · announced Jul 21, 2026 Company release ↗
Source quote
- Jul 21, 2026 · Company release ↗
  “Phanes Therapeutics announces expansion of clinical trial collaboration and supply agreement with Merck to evaluate spevatamig in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jul 21, 2026 Partnership Partnership / licensing announced Jul 21, 2026. Source: company's own press page. source ↗
Sep 5, 2023 Trial start Phase 1/Phase 2: A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) source ↗
Mar 15, 2023 Trial start Phase 1/Phase 2: Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gast source ↗
Aug 11, 2022 Trial start Phase 1/Phase 2: Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) source ↗

Upcoming milestones

2027-12 (ESTIMATED) · Phase 1/Phase 2 · Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesopha · NCT05482893
2027-12 (ESTIMATED) · Phase 1/Phase 2 · A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) · NCT05652686
2027-12 (ESTIMATED) · Phase 1/Phase 2 · Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) · NCT05431270

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jul 21, 2026 Partnership / licensing announced Jul 21, 2026. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT05482893	Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)	Phase 1/Phase 2	Recruiting	Mar 15, 2023	2027-12 (estimated)
NCT05652686	A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)	Phase 1/Phase 2	Recruiting	Sep 5, 2023	2027-12 (estimated)
NCT05431270	Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)	Phase 1/Phase 2	Recruiting	Aug 11, 2022	2027-12 (estimated)